Active, not recruitingNCT07018401
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
Studying Hereditary hemorrhagic telangiectasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Ellen Zhang, MDStanford University
- Intervention
- Pomalidomide(drug)
- Enrollment
- 62 target
- Eligibility
- All sexes
- Timeline
- 2024 – 2026
Study locations (11)
- University of California-San Diego, San Diego, California, United States
- University of California-San Francisco, San Francisco, California, United States
- University of Florida, Gainesville, Florida, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- University of North Carolina, Chapel HIll, Chapel Hill, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Collaborators
The Cleveland Clinic · University of North Carolina, Chapel Hill · University of California, San Francisco · Mayo Clinic · University of Utah · University of California, San Diego · University of Florida · Medical College of Wisconsin · Johns Hopkins University · University of Pennsylvania
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07018401 on ClinicalTrials.govOther trials for Hereditary hemorrhagic telangiectasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07255846A Trial of TER-1754 in Patients With Hereditary Hemorrhagic TelangiectasiaTerremoto Biosciences Inc.
- ENROLLING BY INVITATIONNCT07445347Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia NetworkPoitiers University Hospital
- RECRUITINGPHASE1, PHASE2NCT06659640A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Alnylam Pharmaceuticals
- ENROLLING BY INVITATIONNCT06261333Quality of Life in Patients With Hemorrhagic TelangiectasiaUniversity Hospital, Essen
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03850964Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)Cure HHT
- RECRUITINGNANCT05641142Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic TelangiectasiaUniversity Hospital, Clermont-Ferrand
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05406362Assess Safety and Efficacy of VAD044 in HHT PatientsVaderis Therapeutics AG
- RECRUITINGPHASE2NCT04976036Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) PatientsDr. Romain Lazor